Search results for "Nous"

showing 10 items of 2193 documents

Nonocclusion and Early Reopening of the Great Saphenous Vein After Endovenous Laser Treatment Is Fluence Dependent

2004

Background. Parameters influencing failure and recanalization rates of endovenous laser treatment (ELT) of the great saphenous vein (GSV) are still to be determined. Objective. To evaluate treatment-related parameters of ELT with respect to early failure of occlusion or recanalization of GSVs. Methods. A series of 77 consecutive patients received ELT of 106 GSVs with continuous pullback of the laser fiber. Duplex examination was performed at 1 day, 4 weeks, and 3 months after the procedure. Clinical patient and vessel characteristics as well as technical parameters of the ELT procedure were evaluated via multiple logistic regression analysis. Results. A median vein length of 60 cm (range of…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentDermatologylaw.inventionRecurrenceRisk FactorslawOcclusionmedicineHumansSaphenous VeinThrombusAgedAged 80 and overCentimeterUnivariate analysisMedian Veinbusiness.industryGreat saphenous veinEndovenous laser treatmentGeneral MedicineMiddle Agedmedicine.diseaseLaserSurgeryLogistic ModelsLower ExtremityFemaleSurgeryLaser TherapyNuclear medicinebusinessDermatologic Surgery
researchProduct

Pharmacological thrombolysis: one more weapon for free-flap salvage.

2005

Despite the high success rate of free-tissue transfer, thrombosis still complicates 5-30% of cases. Meticoulous technique, careful vessel selection, and pharmacological prophylaxis are not always enough to avoid thrombosis. Early diagnosis and reintervention provide the only way to salvage a thrombosed free flap, in case of either arterial or venous thrombosis. When kinking, torsion, or external compression of the pedicle are ruled out, and thrombectomy and redo of the anastomosis are unsuccessful, the last resort to save the flap is thrombolytic therapy. The authors present their experience with the salvage of two otherwise lost flaps by means of urokinase thrombolysis through direct intra…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFree flapAnastomosisTHERAPYSurgical FlapsMICROVASCULAR SURGERYFibrinolysismedicineMANAGEMENTHumansThrombolytic TherapyVeinUrokinaseAged 80 and overVenous Thrombosisbusiness.industrySTREPTOKINASE SALVAGEGraft SurvivalThrombolysisTHROMBECTOMYmedicine.diseaseThrombosisUrokinase-Type Plasminogen ActivatorSurgeryVenous thrombosismedicine.anatomical_structureSurgerybusinessmedicine.drugMicrosurgery
researchProduct

[Treatment of sensorineural hearing loss in acute viral otitis media with intratympanic dexamethasone and hyaluronic acid in comparison with intraven…

2006

Background: Intratympanic dexamethasone with hyaluronic acid has shown to be an effective treatment of the inner ear damage in sudden hearing loss and Meniere's disease. It is not known yet if the same applies to the toxic inner ear damage in acute viral otitis media. Patients: Retrospectively, 26 patients who suffered from acute viral otitis media with sensorineural hearing loss were examined with regard to the improvement of their inner ear hearing loss. Twelve patients were treated with intravenous therapy only, consisting of hydroxyethylstarch, pentoxifylline and prednisolone. Fourteen patients additionally received intratympanic injections, consisting of dexamethasone and hyaluronic ac…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHearing Loss SensorineuralPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsEar MiddleDexamethasonePentoxifyllineInjectionsHydroxyethyl Starch DerivativesAdjuvants ImmunologicAudiometryotorhinolaryngologic diseasesmedicineHumansHyaluronic AcidPentoxifyllineInfusions IntravenousDexamethasoneRetrospective StudiesRound windowmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseSurgeryOtitis MediaOtitismedicine.anatomical_structureOtorhinolaryngologyIntravenous therapyAnesthesiaData Interpretation StatisticalAcute DiseasePrednisoloneSensorineural hearing lossDrug Therapy CombinationFemalesense organsmedicine.symptomAudiometrybusinessBone Conductionmedicine.drugLaryngo- rhino- otologie
researchProduct

Impact of Different Texture of Polypropylene Mesh on the Inflammatory Response

2008

Over the past decade, hernia surgery has undergone a considerable transformation with the use of prosthetic materials. The most used polypropylene meshes induce a rapid acute inflammatory response followed by chronic foreign body reaction. Many factors influence this response such as density, size, physical characteristics, different texture and porosity of each biomaterial. The aim of this study is to assess whether the implant of monofilament or multifilament meshes, in the inguinal hernioplasty, determine a different inflammatory response. Thirty-two male patients were included in the study and were randomly divided into two groups. In the first group (MO) inguinal hernioplasty was perf…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyUrologyHernia InguinalPolypropylenesProsthesisLeukocyte CountBasal (phylogenetics)medicineHumansImmunology and AllergyHerniaInflammationPharmacologyPain Postoperativebusiness.industryForeign-Body ReactionInterleukinVenous bloodMiddle AgedSurgical Meshmedicine.diseasePeripheralC-Reactive ProteinCytokinealpha 1-AntitrypsinCytokinesImplantbusinessInternational Journal of Immunopathology and Pharmacology
researchProduct

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Souther…

2000

The combination regimen CPT-11 plus bolus and infusion 5-fluorouracil (5-FU) with high-dose leucovorin (hybrid regimen LV5FU2) has been tested for activity and toxicity against advanced colorectal carcinoma in a randomised, multicenter phase II trial.A total of 102 chemotherapy-naïve patients were randomised in a 1:2 fashion to receive: leucovorin 100 mg/m2 administered as a two-hour infusion before 5-FU 400 mg/m2 as an intravenous bolus, and FU 600 mg/m2 as a 22-hour infusion immediately after 5-FU bolus injection repeated on days 1 and 2 (LV5FU2 regimen, arm A, 34 patients) or CPT-11 at 180 mg/m2 (150 mg/m2 for patients of ageor = 70 and75 years) only on day 1 immediately before LV5FU2 th…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchIrinotecanGastroenterologyDisease-Free SurvivalFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedChemotherapybusiness.industryHematologyMiddle AgedChemotherapy regimenSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.

1998

Summary Background Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent. Administration by continuous infusion and hematopoietic support have rendered dose intensification regimens possible by reducing both hematologic and non-hematologic toxicities. The optimal dose and schedule of ifosfamide when given at high doses remain to be defined. In a previous phase I study, we demonstrated the feasibility of a continuous infusion (c.i.) high-dose ifosfamide (HDI) regimen in the ambulatory setting for patients with advanced solid tumors. The objective of the present phase II study was …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyPhases of clinical researchSoft Tissue NeoplasmsNeutropeniaDrug Administration Schedulechemistry.chemical_compoundGranulocyte Colony-Stimulating FactormedicineHumansIfosfamideInfusions IntravenousAntineoplastic Agents AlkylatingMesnaAgedMesnaChemotherapyIfosfamidebusiness.industrySarcomaHematologyMiddle Agedmedicine.diseaseChemotherapy regimenNitrogen mustardSurgeryRegimenTreatment OutcomeOncologychemistryFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs.

2005

Background. Venous ulcers represent an important medical problem due to their high prevalence and consequent sanitary costs. In this study we evaluated the effect of Prostaglandin E-1 (PGE-1), a drug that improves district ischemia, on the healing of venous ulcers. Methods. We performed a randomized, placebo-controlled, single blind study, in which 87 patients, carriers of venous leg ulcers, homogeneous for dimensions and characteristics, were treated for 20 days an with infusion of Prostaglandin E-1 or placebo, in association with a topic therapy. The dimension and the number of the ulcers were determined at the beginning of the treatment and then every 20 days up to 4 months or until tota…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentVasodilator AgentsIschemiaHealing timeProstaglandinPlacebolaw.inventionVaricose Ulcerchemistry.chemical_compoundRandomized controlled triallawMedicineHumansSingle-Blind MethodAlprostadilAgedLegUltrasonography Doppler DuplexWound Healingbusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesSurgeryClinical trialchemistryBaseline characteristicsVenous ulcers Prostaglandine E-1SurgeryFemaleCardiology and Cardiovascular MedicinebusinessProstaglandin EJournal of vascular surgery
researchProduct

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct

Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosi…

2012

Abstract Although below-knee compression elastic stockings (CES) are effective for the prevention of the postthrombotic syndrome (PTS), a substantial number of patients with deep venous thrombosis still develop PTS. In the present open-label, randomized clinical trial, we compared thigh-length with below-knee CES for the prevention of PTS. A total of 267 patients with the first episode of proximal deep venous thrombosis were randomized to wear either thigh-length or below-knee CES for 2 years. After 3, 6, 12, 18, 24, and 36 months, they were assessed for PTS manifestations according to the Villalta scale. PTS developed in 44 (32.6%) of the 135 patients randomized to thigh-length CES and in …

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsImmunologyThighbehavioral disciplines and activitiesBiochemistryPostthrombotic SyndromeSettore MED/15 - Malattie Del Sanguelaw.inventionPOST-THROMBOTIC SYNDROMEYoung AdultRandomized controlled triallawmedicineHumansKneeAgedAged 80 and overVenous ThrombosisFirst episodeVENOUS THROMBOEMBOLISMbusiness.industryPruritusHazard ratioCell BiologyHematologyMiddle Agedmusculoskeletal systemmedicine.diseaseThrombosishumanitiesConfidence intervalDiscontinuationSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureThighErythemaPatient ComplianceFemalevenous thrombosisbusinessStockings CompressionFollow-Up StudiesBlood
researchProduct

Hepatic Granuloma Due to Propionibacterium acnes in a Patient with Acute Myelogenous Leukemia

2000

AdultMicrobiology (medical)Pathologymedicine.medical_specialtyMyeloidPropionibacterium acnesMyelogenousHumansMedicinePropionibacterium acnesGram-Positive Bacterial InfectionsPropionibacteriaceaeGranulomabiologybusiness.industryLiver Diseasesbiology.organism_classificationmedicine.diseaseRadiographyLeukemia Myeloid AcuteLeukemiaInfectious Diseasesmedicine.anatomical_structureGranulomaImmunologyFemalebusinessHepatic granulomaBacteriaClinical Infectious Diseases
researchProduct